Oculis Holding

OCS

Market cap $1.46B

Oculis Holding AG (OCS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that the transformative potential of its late-stage pipeline, including breakthrough therapy Privosegtor, the novel neuroprotective candidate in development for optic neuropathies, and novel eye drop candidate, OCS-01, for diabetic macular edema, will be highlighted in its company presentation at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that the transformative potential of its late-stage pipeline, including breakthrough therapy Privosegtor, the novel neuroprotective candidate in development for optic neuropathies, and novel eye drop candidate, OCS-01, for diabetic macular edema, will be highlighted in its company presentation at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroid alone at month 3 in the ACUITY trial Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treatment of optic neuritis (ON). Privosegtor, a novel peptoid small molecule designed to cross both the blood–brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuropathies.

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average gain in Low Contrast Visual Acuity (LCVA) of 18 letters compared to IV steroid alone at month 3 in the ACUITY trial ZUG, Switzerland, January 6, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for treatment of optic neuritis (ON). Privosegtor, a novel peptoid small molecule designed to cross both the blood–brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuropathies.

ZUG, Switzerland, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

The consensus price target hints at a 106% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Oculis Holding AG (OCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ZUG, Switzerland, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.